As far as we know, there are no reports that compounds of β-carotene, berberine, and hederagenin interact with MAPK8 and NFE2L2, indicating that MAPK8 and NFE2L2 are probable potential new therapeutic targets for LJF against AD. The gene discussed is NFE2L2; the disease is Alzheimer disease.